A carregar...
Sunitinib in the treatment of metastatic renal cell carcinoma
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer...
Na minha lista:
| Publicado no: | Ther Adv Urol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5117167/ https://ncbi.nlm.nih.gov/pubmed/27904651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287216663979 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|